Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer

Indu Sinha, Kevin Null, William Wolter, Mark A. Suckow, Tonya King, John T. Pinto, Raghu Sinha

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Alternative strategies are needed to control growth of advanced and hormone refractory prostate cancer. In this regard, we investigated the efficacy of methylseleninic acid (MSeA), a penultimate precursor to the highly reactive selenium metabolite, methylselenol, to inhibit growth of invasive and hormone refractory rat (PAIII) and human (PC-3 and PC-3M) prostate cancer cells. Our results demonstrate that MSeA inhibits PAIII cell growth in vitro as well as reduces weights of tumors generated by PAIII cells treated ex vivo. A significant reduction in the number of metastatic lung foci by MSeA treatment was also noted in Lobund-Wistar rats. The PAIII cells along with PC-3, DU145 and PC-3M cells undergo apoptosis after MSeA treatments in both normoxia and hypoxia. Treatment of metastatic rat and human prostate cancer cell lines with MSeA decreased hypoxia-inducible factor-1α (HIF-1α) levels in a dose-dependent manner. Additionally, HIF-1α transcription activity both in normoxic and hypoxic conditions is reduced after MSeA treatment of prostate cancer cells. Furthermore, VEGF and GLUT1, downstream targets of HIF-1α, were also reduced in prostate cancer cells after MSeA treatment. Our study illustrates the efficacy of MSeA in controlling growth of hormone refractory prostate cancer by downregulating HIF-1α, which is possibly occurring through stabilization or increase in prolyl hydroxylase activity.

Original languageEnglish (US)
Pages (from-to)1430-1439
Number of pages10
JournalInternational Journal of Cancer
Volume130
Issue number6
DOIs
StatePublished - Mar 15 2012

Fingerprint

Hypoxia-Inducible Factor 1
Prostatic Neoplasms
Down-Regulation
Growth Hormone
Prolyl Hydroxylases
methylselenic acid
Selenium
Tumor Burden
Vascular Endothelial Growth Factor A
Wistar Rats
Apoptosis
Cell Line
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sinha, Indu ; Null, Kevin ; Wolter, William ; Suckow, Mark A. ; King, Tonya ; Pinto, John T. ; Sinha, Raghu. / Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer. In: International Journal of Cancer. 2012 ; Vol. 130, No. 6. pp. 1430-1439.
@article{12241a6d9f0249b4931a974562a19fb5,
title = "Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer",
abstract = "Alternative strategies are needed to control growth of advanced and hormone refractory prostate cancer. In this regard, we investigated the efficacy of methylseleninic acid (MSeA), a penultimate precursor to the highly reactive selenium metabolite, methylselenol, to inhibit growth of invasive and hormone refractory rat (PAIII) and human (PC-3 and PC-3M) prostate cancer cells. Our results demonstrate that MSeA inhibits PAIII cell growth in vitro as well as reduces weights of tumors generated by PAIII cells treated ex vivo. A significant reduction in the number of metastatic lung foci by MSeA treatment was also noted in Lobund-Wistar rats. The PAIII cells along with PC-3, DU145 and PC-3M cells undergo apoptosis after MSeA treatments in both normoxia and hypoxia. Treatment of metastatic rat and human prostate cancer cell lines with MSeA decreased hypoxia-inducible factor-1α (HIF-1α) levels in a dose-dependent manner. Additionally, HIF-1α transcription activity both in normoxic and hypoxic conditions is reduced after MSeA treatment of prostate cancer cells. Furthermore, VEGF and GLUT1, downstream targets of HIF-1α, were also reduced in prostate cancer cells after MSeA treatment. Our study illustrates the efficacy of MSeA in controlling growth of hormone refractory prostate cancer by downregulating HIF-1α, which is possibly occurring through stabilization or increase in prolyl hydroxylase activity.",
author = "Indu Sinha and Kevin Null and William Wolter and Suckow, {Mark A.} and Tonya King and Pinto, {John T.} and Raghu Sinha",
year = "2012",
month = "3",
day = "15",
doi = "10.1002/ijc.26141",
language = "English (US)",
volume = "130",
pages = "1430--1439",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer. / Sinha, Indu; Null, Kevin; Wolter, William; Suckow, Mark A.; King, Tonya; Pinto, John T.; Sinha, Raghu.

In: International Journal of Cancer, Vol. 130, No. 6, 15.03.2012, p. 1430-1439.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer

AU - Sinha, Indu

AU - Null, Kevin

AU - Wolter, William

AU - Suckow, Mark A.

AU - King, Tonya

AU - Pinto, John T.

AU - Sinha, Raghu

PY - 2012/3/15

Y1 - 2012/3/15

N2 - Alternative strategies are needed to control growth of advanced and hormone refractory prostate cancer. In this regard, we investigated the efficacy of methylseleninic acid (MSeA), a penultimate precursor to the highly reactive selenium metabolite, methylselenol, to inhibit growth of invasive and hormone refractory rat (PAIII) and human (PC-3 and PC-3M) prostate cancer cells. Our results demonstrate that MSeA inhibits PAIII cell growth in vitro as well as reduces weights of tumors generated by PAIII cells treated ex vivo. A significant reduction in the number of metastatic lung foci by MSeA treatment was also noted in Lobund-Wistar rats. The PAIII cells along with PC-3, DU145 and PC-3M cells undergo apoptosis after MSeA treatments in both normoxia and hypoxia. Treatment of metastatic rat and human prostate cancer cell lines with MSeA decreased hypoxia-inducible factor-1α (HIF-1α) levels in a dose-dependent manner. Additionally, HIF-1α transcription activity both in normoxic and hypoxic conditions is reduced after MSeA treatment of prostate cancer cells. Furthermore, VEGF and GLUT1, downstream targets of HIF-1α, were also reduced in prostate cancer cells after MSeA treatment. Our study illustrates the efficacy of MSeA in controlling growth of hormone refractory prostate cancer by downregulating HIF-1α, which is possibly occurring through stabilization or increase in prolyl hydroxylase activity.

AB - Alternative strategies are needed to control growth of advanced and hormone refractory prostate cancer. In this regard, we investigated the efficacy of methylseleninic acid (MSeA), a penultimate precursor to the highly reactive selenium metabolite, methylselenol, to inhibit growth of invasive and hormone refractory rat (PAIII) and human (PC-3 and PC-3M) prostate cancer cells. Our results demonstrate that MSeA inhibits PAIII cell growth in vitro as well as reduces weights of tumors generated by PAIII cells treated ex vivo. A significant reduction in the number of metastatic lung foci by MSeA treatment was also noted in Lobund-Wistar rats. The PAIII cells along with PC-3, DU145 and PC-3M cells undergo apoptosis after MSeA treatments in both normoxia and hypoxia. Treatment of metastatic rat and human prostate cancer cell lines with MSeA decreased hypoxia-inducible factor-1α (HIF-1α) levels in a dose-dependent manner. Additionally, HIF-1α transcription activity both in normoxic and hypoxic conditions is reduced after MSeA treatment of prostate cancer cells. Furthermore, VEGF and GLUT1, downstream targets of HIF-1α, were also reduced in prostate cancer cells after MSeA treatment. Our study illustrates the efficacy of MSeA in controlling growth of hormone refractory prostate cancer by downregulating HIF-1α, which is possibly occurring through stabilization or increase in prolyl hydroxylase activity.

UR - http://www.scopus.com/inward/record.url?scp=84856118899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856118899&partnerID=8YFLogxK

U2 - 10.1002/ijc.26141

DO - 10.1002/ijc.26141

M3 - Article

C2 - 21500193

AN - SCOPUS:84856118899

VL - 130

SP - 1430

EP - 1439

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -